Form 4 for NEO NEOGENOMICS INC
Accepted 2025-02-25 00:00:00 ET · period of report 2025-02-21 · accession 0001077183-25-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-25 | 2025-02-23 | NEO | Olivo Alicia C | EVP, GC, Business Development | M - OptEx | $0.00 | +8,443 | 47.9K | +21% | $0 |
| D | 2025-02-25 | 2025-02-23 | NEO | Olivo Alicia C | EVP, GC, Business Development | F - Tax | $0.00 | -2,504 | 45.4K | -5% | $0 |
| D | 2025-02-25 | 2025-02-23 | NEO | Olivo Alicia C | EVP, GC, Business Development | M - OptEx | $0.00 | -8,443 | 16.9K | -33% | $0 |
| DM | 2025-02-25 | 2025-02-21 | NEO | Olivo Alicia C | EVP, GC, Business Development | A - Grant | $0.00 | +170.7K | 63.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-23 | M | A | 8,443 | $0.00 | 47,857 | D | — | — | (F1) Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. |
| 2 | Common | Common Stock | 2025-02-23 | F | D | 2,504 | $0.00 | 45,353 | D | — | — | (F2) Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. |
| 3 | Derivative | Restricted Stock Unit | 2025-02-23 | M | D | 8,443 | $0.00 | 16,886 | D | $0.00 · — to — | 8,443 Common Stock | (F7) On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. (F6) Once vested, the shares of common stock are not subject to expiration. |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-02-21 | A | A | 107,450 | $0.00 | 107,450 | D | $13.05 · — to 2035-02-21 | 107,450 Common Stock | (F3) This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. (F4) On February 21, 2025, Ms. Olivo was granted 107,450 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| 5 | Derivative | Restricted Stock Unit | 2025-02-21 | A | A | 63,238 | $0.00 | 63,238 | D | $0.00 · — to — | 63,238 Common Stock | (F5) On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. (F6) Once vested, the shares of common stock are not subject to expiration. |